Ivano Riva1, Andreas Katsanos, Irene Floriani, Elena Biagioli, Anastasios G P Konstas, Marco Centofanti, Luciano Quaranta. 1. *Centre for the Study of Glaucoma, University of Brescia, Brescia ‡Laboratory of Clinical Research, IRCCS, Istituto di Ricerche Farmacologiche Mario Negri, Milano ∥DSCMT, University of Tor Vergata, Rome, Italy †Ophthalmology Department, University of Ioannina, Ioannina §Glaucoma Unit, 1st University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece.
Abstract
PURPOSE: The aim of the study was to evaluate the long-term 24-hour intraocular pressure (IOP) efficacy of travoprost monotherapy in primary open-angle glaucoma patients. PATIENTS AND METHODS: A total of 36 previously untreated primary open-angle glaucoma patients were enrolled in this 5-year study. Patients underwent an untreated 24-hour IOP evaluation. Subsequently all patients were assigned to topical therapy with travoprost 0.004% eye-drops preserved with benzalkonium chloride (Travatan, Alcon Laboratories Inc., Fort Worth, TX) administered once in the evening (8:00 PM) in both eyes. All patients were then scheduled for a 24-hour IOP assessment approximately 12 months after the baseline visit. This schedule of follow-up was maintained for the whole duration of the trial. The predetermined range of target IOP reduction selected in this cohort of patients ranged between 20% and 30%. RESULTS: A total of 34 patients completed all phases of the investigation. The mean survival time was 57.3±2.0 months and the cumulative survival rate was 0.82±0.6 at 60 months. Travoprost reduced the mean 24-hour IOP from 23.4±1.7 mm Hg at baseline to 16.8±2.4 mm Hg (28.4%), 16.8±2.5 mm Hg (28.1%), 16.8±2.4 mm Hg (28.5%), 16.7±2.5 mm Hg (28.6%), and 16.9±2.4 mm Hg (27.8%), respectively at the end of the first, second, third, fourth, and fifth year follow-up. No drug-related serious adverse events were registered during the study. CONCLUSIONS: The present study demonstrated the long-term 24-hour efficacy of travoprost for the treatment of primary open-angle glaucoma.
PURPOSE: The aim of the study was to evaluate the long-term 24-hour intraocular pressure (IOP) efficacy of travoprost monotherapy in primary open-angle glaucomapatients. PATIENTS AND METHODS: A total of 36 previously untreated primary open-angle glaucomapatients were enrolled in this 5-year study. Patients underwent an untreated 24-hour IOP evaluation. Subsequently all patients were assigned to topical therapy with travoprost 0.004% eye-drops preserved with benzalkonium chloride (Travatan, Alcon Laboratories Inc., Fort Worth, TX) administered once in the evening (8:00 PM) in both eyes. All patients were then scheduled for a 24-hour IOP assessment approximately 12 months after the baseline visit. This schedule of follow-up was maintained for the whole duration of the trial. The predetermined range of target IOP reduction selected in this cohort of patients ranged between 20% and 30%. RESULTS: A total of 34 patients completed all phases of the investigation. The mean survival time was 57.3±2.0 months and the cumulative survival rate was 0.82±0.6 at 60 months. Travoprost reduced the mean 24-hour IOP from 23.4±1.7 mm Hg at baseline to 16.8±2.4 mm Hg (28.4%), 16.8±2.5 mm Hg (28.1%), 16.8±2.4 mm Hg (28.5%), 16.7±2.5 mm Hg (28.6%), and 16.9±2.4 mm Hg (27.8%), respectively at the end of the first, second, third, fourth, and fifth year follow-up. No drug-related serious adverse events were registered during the study. CONCLUSIONS: The present study demonstrated the long-term 24-hour efficacy of travoprost for the treatment of primary open-angle glaucoma.
Authors: Shamira A Perera; Daniel Sw Ting; Monisha E Nongpiur; Paul T Chew; Maria Cecilia D Aquino; Chelvin Ca Sng; Sue-Wei Ho; Tin Aung Journal: Clin Ophthalmol Date: 2016-04-26
Authors: Luciano Quaranta; Ivano Riva; Andreas Katsanos; Irene Floriani; Marco Centofanti; Anastasios G P Konstas Journal: Clin Ophthalmol Date: 2015-04-10
Authors: Andreas Katsanos; Anastasios G Konstas; Dimitrios G Mikropoulos; Luciano Quaranta; Irini C Voudouragkaki; Georgios P Athanasopoulos; Ioannis Asproudis; Miguel A Teus Journal: Adv Ther Date: 2018-04-11 Impact factor: 3.845